William I Bensinger

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. Bensinger W, Maziarz R, Jagannath S, Spencer A, Durrant S, Becker P, et al. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol. 2012;159:58-66 pubmed publisher
    ..These findings indicate that single-agent lucatumumab was well tolerated up to 4·5 mg/kg with modest clinical activity in relapsed/refractory MM, warranting further study as a combination therapy. ..
  2. Bensinger W. Allogeneic stem cell transplantation for multiple myeloma. Hematol Oncol Clin North Am. 2014;28:891-902 pubmed publisher
    ..These approaches include vaccines, monoclonal antibodies, and adoptive immunotherapies. ..
  3. Bensinger W. Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia. 2009;23:442-8 pubmed publisher
  4. request reprint
    Bensinger W. The current status of hematopoietic stem cell transplantation for multiple myeloma. Clin Adv Hematol Oncol. 2004;2:46-52 pubmed
  5. Bensinger W. Allogeneic transplantation: peripheral blood vs. bone marrow. Curr Opin Oncol. 2012;24:191-6 pubmed publisher
    ..PBSCs are a preferred source of stem cells for many types of allogeneic transplant, in which matched related donors are available. Whether the same benefits accrue from unrelated donors will require further follow-up. ..